FDA. Guidance For Industry. Investigator Responsibilities – Protecting The Rights, Safety, And Welfare Of Study Subjects.

I. INTRODUCTION

This guidance represents the Food and Drug Administration’s (FDA’s) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the FDA staff responsible for implementing this guidance. If you cannot identify the appropriate FDA staff, call the appropriate number listed on the title page of this guidance.

This guidance provides an overview of the responsibilities of a person who conducts a clinical investigation of a drug, biological product, or medical device (an investigator as defined in 21 CFR 312.3(b) and 21 CFR 812.3(i)). The goal of this guidance is to help investigators better meet their responsibilities with respect to protecting human subjects and ensuring the integrity of the data from clinical investigations. This guidance is intended to clarify for investigators and sponsors FDA’s expectations concerning the investigator’s responsibility (1) to supervise a clinical study in which some study tasks are delegated to employees or colleagues of the investigator or other third parties and (2) to protect the rights, safety, and welfare of study subjects.

FDA’s guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe the Agency’s current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in Agency guidances means that something is suggested or recommended, but not required.

Source.

Authors:

Center for Drug Evaluation and Research
Center for Devices and Radiological Health
Center for Biologics Evaluation and Research

OCTOBER 2009

 

Clinical Research News

GLP-1 et fertilité : pourquoi les médicaments pour la perte de poids font débat en médecine de la reproduction
Lp(a) élevée : un nouvel essai pour tester une combinaison de médicaments contre le risque cardiaque héréditaire
Les médicaments pour la perte de poids associés à un risque plus faible de certains cancers : ce que montrent les nouvelles données
Après un AVC et une hémorragie cérébrale : un nouvel essai évalue quand les anticoagulants sont nécessaires
Le premier vaccin conçu par l'IA termine ses essais sur l'homme
Blood in Urine and Suspected Tumor: New Urine Test to be Compared Against Cystoscopy and Biopsy
When Ultrasound Shows an Anomaly but Genetics Are Silent: Whole-Genome Sequencing (WGS) Put to the Test

Prochains essais cliniques

Clinical Research Jobs

More jobs

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

S'abonner